Product Description
a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting (Sourced from: https://pubmed.ncbi.nlm.nih.gov/18983233/)
Mechanisms of Action: NK1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | China | Colombia | Croatia | Dominican Republic | Egypt | Estonia | Germany | Hong Kong | Hungary | India | Italy | Japan | Malaysia | Mexico | Netherlands | New Zealand | Norway | Philippines | Russia | South Africa | Spain | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Venezuela
Approved Indications: None
Company: Merck
Company Location: Eastern America
Company Founding Year: 1668
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Multiple Myeloma|Oncology Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07413809 |
NCT07413809 | P3 |
Recruiting |
Multiple Myeloma |
2027-09-01 |
2026-02-18 |
Primary Endpoints|Treatments |
|
2018-000663-80 |
2018-000663-80 | P3 |
Active, not recruiting |
Oncology Unspecified |
2019-05-11 |
2025-06-29 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |